• 1
    WHO The top 10 causes of death.
  • 2
    Murphy SL, Xu J, Kochanek KD (2013) Deaths: Final Data for 2010. National Vital Statistics Reports 61.
  • 3
    Webb SA, Pettila V, Seppelt I et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009; 361:19251934.
  • 4
    Gill JR, Sheng ZM, Ely SF et al. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med 2010; 134:235243.
  • 5
    Lee EH, Wu C, Lee EU et al. Fatalities associated with the 2009 H1N1 influenza A virus in New York city. Clin Infect Dis 2010; 50:14981504.
  • 6
    Mauad T, Hajjar LA, Callegari GD et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med 2010; 181:7279.
  • 7
    Rice TW, Rubinson L, Uyeki TM et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med 2012; 40:14871498.
  • 8
    Henderson FW, Collier AM, Sanyal MA et al. A longitudinal study of respiratory viruses and bacteria in the etiology of acute otitis media with effusion. N Engl J Med 1982; 306:13771383.
  • 9
    Ruuskanen O, Arola M, Putto-Laurila A et al. Acute otitis media and respiratory virus infections. Pediatr Infect Dis J 1989; 8:9499.
  • 10
    Bulut Y, Guven M, Otlu B et al. Acute otitis media and respiratory viruses. Eur J Pediatr 2007; 166:223228.
  • 11
    Chonmaitree T, Revai K, Grady JJ et al. Viral upper respiratory tract infection and otitis media complication in young children. Clin Infect Dis 2008; 46:815823.
  • 12
    Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci USA 2005; 102:1289112896.
  • 13
    Pettigrew MM, Gent JF, Pyles RB, Miller AL, Nokso-Koivisto J, Chonmaitree T. Viral-bacterial interactions and risk of acute otitis media complicating upper respiratory tract infection. J Clin Microbiol 2011; 49:37503755.
  • 14
    Bakaletz LO. Immunopathogenesis of polymicrobial otitis media. J Leukoc Biol 2010; 87:213222.
  • 15
    Pitkaranta A, Jero J, Arruda E, Virolainen A, Hayden FG. Polymerase chain reaction-based detection of rhinovirus, respiratory syncytial virus, and coronavirus in otitis media with effusion. J Pediatr 1998; 133:390394.
  • 16
    Pitkaranta A, Roivainen M, Blomgren K et al. Presence of viral and bacterial pathogens in the nasopharynx of otitis-prone children. A prospective study. Int J Pediatr Otorhinolaryngol 2006; 70:647654.
  • 17
    Glezen P, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973; 288:498505.
  • 18
    Murphy TF, Henderson FW, Clyde WA Jr, Collier AM, Denny FW. Pneumonia: an eleven-year study in a pediatric practice. Am J Epidemiol 1981; 113:1221.
  • 19
    Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008; 198:962970.
  • 20
    Stuart-Harris CH, Laird J, Tyrrell DA, Kelsall MH, Pownall M. The relationship between influenza and pneumonia. J Hyg 1949; 47:434448.
  • 21
    Oswald NC, Shooter RA, Curwen MP. Pneumonia complicating Asian influenza. Br Med J 1958; 2:13051311.
  • 22
    Tyrrell DA. The pulmonary complications of influenza as seen in Sheffield in 1949. Q J Med 1952; 21:291306.
  • 23
    Louria DB, Blumenfeld HL, Ellis JT, Kilbourne ED, Rogers DE. Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. J Clin Investig 1959; 38:213265.
  • 24
    Bisno AL, Griffin JP, Van Epps KA, Niell HB, Rytel MW. Pneumonia and Hong Kong influenza: a prospective study of the 1968-1969 epidemic. Am J Med Sci 1971; 261:251263.
  • 25
    McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 2003; 187:10001009.
  • 26
    Peltola VT, McCullers JA. Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatr Infect Dis J 2004; 23:S87S97.
  • 27
    Peltola VT, Murti KG, McCullers JA. Influenza virus neuraminidase contributes to secondary bacterial pneumonia. J Infect Dis 2005; 192:249257.
  • 28
    McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006; 19:571582.
  • 29
    Zhou H, Haber M, Ray S, Farley MM, Panozzo CA, Klugman KP. Invasive pneumococcal pneumonia and respiratory virus co-infections. Emerg Infect Dis 2012; 18:294297.
  • 30
    McCullers JA. Preventing and treating secondary bacterial infections with antiviral agents. Antivir Ther 2011; 16:123135.
  • 31
    Louie JK, Acosta M, Winter K et al. (2009) Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 302: 18961902.
  • 32
    Cilloniz C, Ewig S, Menendez R et al. Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia. J Infec 2012; 65:223230.
  • 33
    Martin-Loeches I, Sanchez-Corral A, Diaz E et al. Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) virus. Chest 2011; 139:555562.
  • 34
    Randolph AG, Vaughn F, Sullivan R et al. Critically ill children during the 2009-2010 influenza pandemic in the United States. Pediatrics 2011; 128:e1450e1458.
  • 35
    Shieh WJ, Blau DM, Denison AM et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol 2010; 177:166175.
  • 36
    Harms PW, Schmidt LA, Smith LB et al. Autopsy findings in eight patients with fatal H1N1 influenza. Am J Clin Pathol 2010; 134:2735.
  • 37
    Cox CM, Blanton L, Dhara R, Brammer L, Finelli L. 2009 Pandemic influenza A (H1N1) deaths among children–United States, 2009-2010. Clin Infect Dis 2011; 52(Suppl 1):S69S74.
  • 38
    Weinberger DM, Simonsen L, Jordan R, Steiner C, Miller M, Viboud C. Impact of the 2009 influenza pandemic on pneumococcal pneumonia hospitalizations in the United States. J Infect Dis 2012; 205:458465.
  • 39
    Nelson GE, Gershman KA, Swerdlow DL, Beall BW, Moore MR. Invasive pneumococcal disease and pandemic (H1N1) 2009, Denver, Colorado, USA. Emerg Infect Dis 2012; 18:208216.
  • 40
    Fleming-Dutra KE, Taylor T, Link-Gelles R et al. Effect of the 2009 influenza A(H1N1) pandemic on invasive pneumococcal pneumonia. J Infect Dis 2013; 207:11351143.
  • 41
    Ampofo K, Bender J, Sheng X et al. Seasonal invasive pneumococcal disease in children: role of preceding respiratory viral infection. Pediatrics 2008; 122:229237.
  • 42
    Kim PE, Musher DM, Glezen WP, Rodriguez-Barradas MC, Nahm WK, Wright CE. Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. Clin Infect Dis 1996; 22:100106.
  • 43
    Talbot TR, Poehling KA, Hartert TV et al. Seasonality of invasive pneumococcal disease: temporal relation to documented influenza and respiratory syncytial viral circulation. Am J Med 2005; 118:285291.
  • 44
    Murdoch DR, Jennings LC. Association of respiratory virus activity and environmental factors with the incidence of invasive pneumococcal disease. J Infec 2009; 58:3746.
  • 45
    Honkinen M, Lahti E, Osterback R, Ruuskanen O, Waris M. Viruses and bacteria in sputum samples of children with community-acquired pneumonia. Clin Microbiol Infec 2012; 18:300307.
  • 46
    Korppi M. Mixed viral-bacterial pulmonary infections in children. Pediatr Pulmonol Suppl 1999; 18:110112.
  • 47
    Michelow IC, Olsen K, Lozano J et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 2004; 113:701707.
  • 48
    Tsolia MN, Psarras S, Bossios A et al. Etiology of community-acquired pneumonia in hospitalized school-age children: evidence for high prevalence of viral infections. Clin Infect Dis 2004; 39:681686.
  • 49
    Rudan I, O'Brien KL, Nair H et al. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health 2013; 3:10401.
  • 50
    Jennings LC, Anderson TP, Beynon KA et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008; 63:4248.
  • 51
    Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest 2008; 134:11411148.
  • 52
    McCullers JA, Rehg JE. Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor. J Infect Dis 2002; 186:341350.
  • 53
    Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med 2008; 14:558564.
  • 54
    Shahangian A, Chow EK, Tian X et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Investig 2009; 119:19101920.
  • 55
    Ballinger MN, Standiford TJ. Postinfluenza bacterial pneumonia: host defenses gone awry. J Interferon Cytokine Res 2010; 30:643652.
  • 56
    Carson JL, Collier AM, Hu SS. Acquired ciliary defects in nasal epithelium of children with acute viral upper respiratory infections. N Engl J Med 1985; 312:463468.
  • 57
    Pittet LA, Hall-Stoodley L, Rutkowski MR, Harmsen AG. Influenza virus infection decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae. Am J Respir Cell Mol Biol 2010; 42:450460.
  • 58
    Selinger DS, Reed WP, McLaren LC. Model for studying bacterial adherence to epithelial cells infected with viruses. Infect Immun 1981; 32:941944.
  • 59
    Plotkowski MC, Puchelle E, Beck G, Jacquot J, Hannoun C. Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am Rev Respir Dis 1986; 134:10401044.
  • 60
    Avadhanula V, Rodriguez CA, Devincenzo JP et al. Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner. J Virol 2006; 80:16291636.
  • 61
    van der Sluijs KF, van Elden LJ, Nijhuis M et al. Involvement of the platelet-activating factor receptor in host defense against Streptococcus pneumoniae during postinfluenza pneumonia. Am J Physiol Lung Cell Mol Physiol 2006; 290:L194L199.
  • 62
    Diavatopoulos DA, Short KR, Price JT et al. Influenza A virus facilitates Streptococcus pneumoniae transmission and disease. FASEB J 2010; 24:17891798.
  • 63
    Nakamura S, Davis KM, Weiser JN. Synergistic stimulation of type I interferons during influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice. J Clin Investig 2011; 121:36573665.
  • 64
    Short KR, Reading PC, Wang N, Diavatopoulos DA, Wijburg OL Increased nasopharyngeal bacterial titers and local inflammation facilitate transmission of Streptococcus pneumoniae. mBio [Research Support, Non-U.S. Gov't] 2012;3:e0025512.
  • 65
    McCullers JA, McAuley JL, Browall S et al. Influenza enhances susceptibility to natural acquisition of and disease due to Streptococcus pneumoniae in ferrets. J Infect Dis 2010; 202:12871295.
  • 66
    Kleinerman ES, Daniels CA, Polisson RP, Snyderman R. Effect of virus infection on the inflammatory response. Depression of macrophage accumulation in influenza-infected mice. Am J Pathol 1976; 85:373382.
  • 67
    Kleinerman ES, Snyderman R, Daniels CA. Depressed monocyte chemotaxis during acute influenza infection. Lancet 1975; 2:10631066.
  • 68
    Kleinerman ES, Snyderman R, Daniels CA. Depression of human monocyte chemotaxis by herpes simplex and influenza viruses. J Immunol 1974; 113:15621567.
  • 69
    Astry CL, Jakab GJ. Influenza virus-induced immune complexes suppress alveolar macrophage phagocytosis. J Virol 1984; 50:287292.
  • 70
    Jakab GJ. Immune impairment of alveolar macrophage phagocytosis during influenza virus pneumonia. Am Rev Respir Dis 1982; 126:778782.
  • 71
    Jakab GJ, Warr GA, Knight ME. Pulmonary and systemic defenses against challenge with Staphylococcus aureus in mice with pneumonia due to influenza A virus. J Infect Dis 1979; 140:105108.
  • 72
    Nickerson CL, Jakab GJ. Pulmonary antibacterial defenses during mild and severe influenza virus infection. Infect Immun 1990; 58:28092814.
  • 73
    Raza MW, Blackwell CC, Elton RA, Weir DM. Bactericidal activity of a monocytic cell line (THP-1) against common respiratory tract bacterial pathogens is depressed after infection with respiratory syncytial virus. J Med Microbiol 2000; 49:227233.
  • 74
    Craft AW, Reid MM, Low WT. Effect of virus infections on polymorph function in children. Br Med J 1976; 1:1570.
  • 75
    Ruutu P. Depression of rat neutrophil exudation and motility by influenza virus. Scand J Immunol 1977; 6:11131120.
  • 76
    Ruutu P, Vaheri A, Kosunen TU. Depression of human neutrophil motility by influenza virus in vitro. Scand J Immunol 1977; 6:897906.
  • 77
    Schlesinger JJ, Ernst C, Weinstein L. Letter: inhibition of human neutrophil chemotaxis by influenza virus. Lancet 1976; 1:650651.
  • 78
    Larson HE, Parry RP, Tyrrell DA. Impaired polymorphonuclear leucocyte chemotaxis after influenza virus infection. British J Dis Chest 1980; 74:5662.
  • 79
    Martin RR, Couch RB, Greenberg SB, Cate TR, Warr GA. Effects of infection with influenza virus on the function of polymorphonuclear leukocytes. J Infect Dis 1981; 144:279280.
  • 80
    Larson HE, Blades R. Impairment of human polymorphonuclear leucocyte function by influenza virus. Lancet 1976; 1:283.
  • 81
    Abramson JS, Mills EL. Depression of neutrophil function induced by viruses and its role in secondary microbial infections. Rev Infect Dis 1988; 10:326341.
  • 82
    Didierlaurent A, Goulding J, Patel S et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 2008; 205:323329.
  • 83
    Kudva A, Scheller EV, Robinson KM et al. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol 2011; 186:16661674.
  • 84
    Li W, Moltedo B, Moran TM. Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of gammadelta T cells. J Virol 2012; 86:1230412312.
  • 85
    Tian X, Xu F, Lung WY et al. Poly I:C enhances susceptibility to secondary pulmonary infections by gram-positive bacteria. PLoS ONE 2012; 7:e41879.
  • 86
    de Jong MD, Simmons CP, Thanh TT et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:12031207.
  • 87
    Kobasa D, Takada A, Shinya K et al. Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus. Nature 2004; 431:703707.
  • 88
    Zheng BJ, Chan KW, Lin YP et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008; 105:80918096.
  • 89
    Seki M, Yanagihara K, Higashiyama Y et al. Immunokinetics in severe pneumonia due to influenza virus and bacteria coinfection in mice. Eur Respir J 2004; 24:143149.
  • 90
    Zavitz CC, Bauer CM, Gaschler GJ et al. Dysregulated macrophage-inflammatory protein-2 expression drives illness in bacterial superinfection of influenza. J Immunol 2010; 184:20012013.
  • 91
    Simmons C, Farrar J. Insights into inflammation and influenza. N Engl J Med 2008; 359:16211623.
  • 92
    Sun J, Madan R, Karp CL, Braciale TJ. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat Med 2009; 15:277284.
  • 93
    van der Sluijs KF, Nijhuis M, Levels JH et al. Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia. J Infect Dis 2006; 193:214222.
  • 94
    van der Sluijs KF, van Elden LJ, Nijhuis M et al. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol 2004; 172:76037609.
  • 95
    WHO (2012) Global routine vaccination coverage,2011. Releve epidemiologique hebdomadaire/Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record/Health Section of the Secretariat of the League of Nations; 87: 432435.
  • 96
    Madhi SA, Ludewick H, Kuwanda L et al. Pneumococcal coinfection with human metapneumovirus. J Infect Dis 2006; 193:12361243.
  • 97
    Simonsen L, Taylor RJ, Young-Xu Y et al. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. mBio 2011; 2:e00309e00310.
  • 98
    Dominguez A, Castilla Catalan J, Godoy P et al. Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009-2010 and 2010-2011 seasons. Hum Vaccin Immunother 2013; 9:330334.
  • 99
    Dominguez A, Castilla J, Godoy P et al. Benefit of conjugate pneumococcal vaccination in preventing influenza hospitalization in children: a case-control study. Pediatr Infect Dis J 2013; 32:330334.
  • 100
    Govaert TM, Thijs CT, Masurel N et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994; 272:16611665.
  • 101
    Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007; 357:13731381.
  • 102
    Clements DA, Langdon L, Bland C, Walter E. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Arch Pediatr Adolesc Med 1995; 149:11131117.
  • 103
    Ohmit SE, Monto AS. Influenza vaccine effectiveness in preventing hospitalization among the elderly during influenza type A and type B seasons. Int J Epidemiol 1995; 24:12401248.
  • 104
    Ozgur SK, Beyazova U, Kemaloglu YK et al. Effectiveness of inactivated influenza vaccine for prevention of otitis media in children. Pediatr Infect Dis J 2006; 25:401404.
  • 105
    Foster DA, Talsma A, Furumoto-Dawson A et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992; 136:296307.
  • 106
    Miller WT Jr, Mickus TJ, Barbosa E Jr et al. CT of viral lower respiratory tract infections in adults: comparison among viral organisms and between viral and bacterial infections. AJR Am J Roentgenol 2011; 197:10881095.
  • 107
    Flanders SA, Stein J, Shochat G et al. Performance of a bedside C-reactive protein test in the diagnosis of community-acquired pneumonia in adults with acute cough. Am J Med 2004; 116:529535.
  • 108
    Schuetz P, Amin DN, Greenwald JL. Role of procalcitonin in managing adult patients with respiratory tract infections. Chest 2012; 141:10631073.
  • 109
    Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004; 350:451458.
  • 110
    Muller B, Gencay MM, Gibot S et al. Circulating levels of soluble triggering receptor expressed on myeloid cells (sTREM)-1 in community-acquired pneumonia. Crit Care Med 2007; 35:990991.
  • 111
    Cuquemelle E, Soulis F, Villers D et al. Can procalcitonin help identify associated bacterial infection in patients with severe influenza pneumonia? A multicentre study. Intensive Care Med 2011; 37:796800.
  • 112
    Bjerrum L, Gahrn-Hansen B, Munck AP. C-reactive protein measurement in general practice may lead to lower antibiotic prescribing for sinusitis. Br J Gen Pract 2004; 54:659662.
  • 113
    Cals JW, Butler CC, Hopstaken RM, Hood K, Dinant GJ. Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. BMJ 2009; 338:b1374.
  • 114
    Cals JW, Schot MJ, de Jong SA, Dinant GJ, Hopstaken RM. Point-of-care C-reactive protein testing and antibiotic prescribing for respiratory tract infections: a randomized controlled trial. Annals of family medicine 2010; 8:124133.
  • 115
    Christ-Crain M, Jaccard-Stolz D, Bingisser R et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600607.
  • 116
    Stolz D, Christ-Crain M, Bingisser R et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131:919.
  • 117
    Schuetz P, Christ-Crain M, Thomann R et al. (2009) Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 302: 10591066.
  • 118
    Burkhardt O, Ewig S, Haagen U et al. Procalcitonin guidance and reduction of antibiotic use in acute respiratory tract infection. Eur Respir J 2010; 36:601607.
  • 119
    Haran JP, Beaudoin FL, Suner S, Lu S. C-reactive protein as predictor of bacterial infection among patients with an influenza-like illness. Am J Emerg Med 2013; 31:137144.
  • 120
    Diez-Padrisa N, Bassat Q, Machevo S et al. Procalcitonin and C-reactive protein for invasive bacterial pneumonia diagnosis among children in Mozambique, a malaria-endemic area. PLoS ONE 2010; 5:e13226.
  • 121
    (ALAT) GdtdlALdT (2004) Update to the Latin American Thoracic Association (ALAT) recommendations on community acquired pneumonia. Arch Bronconeumol 40: 364374.
  • 122
    Japanese Respiratory Society (2006) Guidelines for the management of community acquired pneumonia in adults, revised edition. Respirology 11 Suppl 3: S79S133.
  • 123
    South African Thoracic Society Working Group (2007) Management of community-acquired pneumonia in adults. South African Med J = Suid-Afrikaanse tydskrif vir geneeskunde 97: 12961306.
  • 124
    Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27S72.
  • 125
    Lim WS, Baudouin SV, George RC et al. (2009) BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 64 Suppl 3: iii1iii55.
  • 126
    Correa Rde A, Lundgren FL, Pereira-Silva JL et al. Brazilian guidelines for community-acquired pneumonia in immunocompetent adults - 2009. J Bras Pneumol 2009; 35:574601.
  • 127
    Bradley JS, Byington CL, Shah SS et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25e76.
  • 128
    Gupta D, Agarwal R, Aggarwal AN et al. Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: joint ICS/NCCP(I) recommendations. Lung India 2012; 29:S27S62.
  • 129
    Mandell LA. Severe community-acquired pneumonia (CAP) and the Infectious Diseases Society of America/American Thoracic Society CAP guidelines prediction rule: validated or not. Clin Infect Dis 2009; 48:386388.
  • 130
    Spindler C, Stralin K, Eriksson L et al. Swedish guidelines on the management of community-acquired pneumonia in immunocompetent adults–Swedish Society of Infectious Diseases 2012. Scand J Infect Dis 2012; 44:885902.
  • 131
    Almirall J, Bolibar I, Vidal J et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000; 15:757763.
  • 132
    Wiemken TL, Peyrani P, Ramirez JA. Global changes in the epidemiology of community-acquired pneumonia. Semin Respir Crit Care Med 2012; 33:213219.
  • 133
    Zar HJ. Pneumonia in HIV-infected and HIV-uninfected children in developing countries: epidemiology, clinical features, and management. Curr Opin Pulm Med 2004; 10:176182.
  • 134
    CDC (2003) Drug-Resistant Streptococcus pneumoniae (DRSP) Surveillance Manual.
  • 135
  • 136
    Aujesky D, Auble TE, Yealy DM et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005; 118:384392.
  • 137
    Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections–full version. Clin Microbiol Infec: Offic Pub Europ Soci Clin Microbiol Infec Dis 2011; 17(Suppl 6):E1E59.
  • 138
    Bright RA, Medina MJ, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366:11751181.
  • 139
    Leang SK, Deng YM, Shaw R et al. Influenza antiviral resistance in the Asia-Pacific region during 2011. Antiviral Res 2013; 97:206210.
  • 140
    Viasus D, Pano-Pardo JR, Pachon J et al. Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection. Chest 2011; 140:10251032.
  • 141
    McCullers JA. Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. J Infect Dis 2004; 190:519526.
  • 142
    Hernan MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011; 53:277279.
  • 143
    Hayden FG, Osterhaus AD, Treanor JJ et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997; 337:874880.
  • 144
    Kaiser L, Keene ON, Hammond JM, Elliott M, Hayden FG. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000; 160:32343240.
  • 145
    Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:16671672.
  • 146
    Nicholson KG, Aoki FY, Osterhaus AD et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355:18451850.
  • 147
    Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283: 10161024.
  • 148
    Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127133.
  • 149
    Hsu J, Santesso N, Mustafa R et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 2012; 156:512524.
  • 150
    Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis 2013; 207:553563.
  • 151
    Kim SH, Hong SB, Yun SC et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011; 183:12071214.
  • 152
    Brun-Buisson C, Richard JC, Mercat A, Thiebaut AC, Brochard L. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011; 183:12001206.